Diagnostic Microdosing Approach to Study Gemcitabine Resistance

Tiffany M. Scharadin, Hongyong Zhang, Maike Zimmermann, Sisi Wang, Michael A Malfatti, George D. Cimino, Kenneth Turteltaub, Ralph De Vere White, Chong Xian Pan, Paul T. Henderson

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. We determined whether subtherapeutic "microdoses" of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with various concentrations of 14C-labeled gemcitabine for 4-24 h. Drug incorporation into DNA was determined by accelerator mass spectrometry. A mechanistic analysis determined that RRM2, a DNA synthesis protein and a known resistance factor, substantially mediated gemcitabine toxicity. These results support gemcitabine levels in DNA as a potential biomarker of drug cytotoxicity.

Original languageEnglish (US)
Pages (from-to)1843-1848
Number of pages6
JournalChemical Research in Toxicology
Volume29
Issue number11
DOIs
StatePublished - Nov 21 2016

ASJC Scopus subject areas

  • Toxicology

Fingerprint Dive into the research topics of 'Diagnostic Microdosing Approach to Study Gemcitabine Resistance'. Together they form a unique fingerprint.

  • Cite this